vs

Side-by-side financial comparison of Axogen, Inc. (AXGN) and WESTAMERICA BANCORPORATION (WABC). Click either name above to swap in a different company.

WESTAMERICA BANCORPORATION is the larger business by last-quarter revenue ($63.3M vs $61.5M, roughly 1.0× Axogen, Inc.). WESTAMERICA BANCORPORATION runs the higher net margin — 43.9% vs -31.9%, a 75.8% gap on every dollar of revenue. On growth, Axogen, Inc. posted the faster year-over-year revenue change (26.6% vs -9.0%). WESTAMERICA BANCORPORATION produced more free cash flow last quarter ($119.7M vs $-1.4M). Over the past eight quarters, Axogen, Inc.'s revenue compounded faster (13.3% CAGR vs -8.6%).

Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering (IPO). Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is...

Westamerica Bancorporation is a regional bank holding company headquartered in California, U.S. It operates via its wholly owned banking subsidiary to provide full-spectrum retail and commercial banking services, including deposit products, business and consumer loans, wealth management, and payment services, primarily serving individual consumers, SMEs and local institutional clients in northern and central California.

AXGN vs WABC — Head-to-Head

Bigger by revenue
WABC
WABC
1.0× larger
WABC
$63.3M
$61.5M
AXGN
Growing faster (revenue YoY)
AXGN
AXGN
+35.6% gap
AXGN
26.6%
-9.0%
WABC
Higher net margin
WABC
WABC
75.8% more per $
WABC
43.9%
-31.9%
AXGN
More free cash flow
WABC
WABC
$121.0M more FCF
WABC
$119.7M
$-1.4M
AXGN
Faster 2-yr revenue CAGR
AXGN
AXGN
Annualised
AXGN
13.3%
-8.6%
WABC

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AXGN
AXGN
WABC
WABC
Revenue
$61.5M
$63.3M
Net Profit
$-19.6M
$27.8M
Gross Margin
75.2%
Operating Margin
20.2%
59.8%
Net Margin
-31.9%
43.9%
Revenue YoY
26.6%
-9.0%
Net Profit YoY
-410.8%
-12.3%
EPS (diluted)
$-0.38
$1.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXGN
AXGN
WABC
WABC
Q1 26
$61.5M
Q4 25
$59.9M
$63.3M
Q3 25
$60.1M
$63.7M
Q2 25
$56.7M
$64.6M
Q1 25
$48.6M
$66.4M
Q4 24
$49.4M
$69.6M
Q3 24
$48.6M
$74.1M
Q2 24
$47.9M
$74.3M
Net Profit
AXGN
AXGN
WABC
WABC
Q1 26
$-19.6M
Q4 25
$-13.2M
$27.8M
Q3 25
$708.0K
$28.3M
Q2 25
$579.0K
$29.1M
Q1 25
$-3.8M
$31.0M
Q4 24
$450.0K
$31.7M
Q3 24
$-1.9M
$35.1M
Q2 24
$-1.9M
$35.5M
Gross Margin
AXGN
AXGN
WABC
WABC
Q1 26
75.2%
Q4 25
74.1%
Q3 25
76.6%
Q2 25
74.2%
Q1 25
71.9%
Q4 24
76.1%
Q3 24
74.9%
Q2 24
73.8%
Operating Margin
AXGN
AXGN
WABC
WABC
Q1 26
20.2%
Q4 25
-16.3%
59.8%
Q3 25
3.2%
59.5%
Q2 25
3.0%
60.5%
Q1 25
-3.4%
63.0%
Q4 24
4.1%
62.8%
Q3 24
-0.6%
64.5%
Q2 24
-0.9%
64.8%
Net Margin
AXGN
AXGN
WABC
WABC
Q1 26
-31.9%
Q4 25
-22.0%
43.9%
Q3 25
1.2%
44.3%
Q2 25
1.0%
45.0%
Q1 25
-7.9%
46.7%
Q4 24
0.9%
45.6%
Q3 24
-3.8%
47.3%
Q2 24
-4.0%
47.8%
EPS (diluted)
AXGN
AXGN
WABC
WABC
Q1 26
$-0.38
Q4 25
$-0.28
$1.12
Q3 25
$0.01
$1.12
Q2 25
$0.01
$1.12
Q1 25
$-0.08
$1.16
Q4 24
$-0.00
$1.19
Q3 24
$-0.04
$1.31
Q2 24
$-0.04
$1.33

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXGN
AXGN
WABC
WABC
Cash + ST InvestmentsLiquidity on hand
$82.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$244.8M
$933.5M
Total Assets
$289.5M
$6.0B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXGN
AXGN
WABC
WABC
Q1 26
$82.7M
Q4 25
$41.5M
Q3 25
$35.8M
Q2 25
$29.9M
Q1 25
$22.1M
Q4 24
$33.5M
Q3 24
$24.5M
Q2 24
$21.1M
Total Debt
AXGN
AXGN
WABC
WABC
Q1 26
Q4 25
$48.4M
Q3 25
$48.2M
Q2 25
$47.9M
Q1 25
$47.7M
Q4 24
$47.5M
Q3 24
$47.3M
Q2 24
$47.0M
Stockholders' Equity
AXGN
AXGN
WABC
WABC
Q1 26
$244.8M
Q4 25
$128.8M
$933.5M
Q3 25
$120.8M
$931.6M
Q2 25
$112.3M
$921.8M
Q1 25
$105.4M
$923.1M
Q4 24
$103.9M
$890.0M
Q3 24
$99.4M
$909.0M
Q2 24
$95.7M
$815.6M
Total Assets
AXGN
AXGN
WABC
WABC
Q1 26
$289.5M
Q4 25
$221.7M
$6.0B
Q3 25
$216.4M
$5.9B
Q2 25
$205.5M
$5.8B
Q1 25
$196.2M
$6.0B
Q4 24
$203.7M
$6.1B
Q3 24
$192.0M
$6.2B
Q2 24
$188.9M
$6.3B
Debt / Equity
AXGN
AXGN
WABC
WABC
Q1 26
Q4 25
0.38×
Q3 25
0.40×
Q2 25
0.43×
Q1 25
0.45×
Q4 24
0.46×
Q3 24
0.48×
Q2 24
0.49×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXGN
AXGN
WABC
WABC
Operating Cash FlowLast quarter
$121.9M
Free Cash FlowOCF − Capex
$-1.4M
$119.7M
FCF MarginFCF / Revenue
-2.3%
189.0%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
4.38×
TTM Free Cash FlowTrailing 4 quarters
$9.1M
$213.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXGN
AXGN
WABC
WABC
Q1 26
Q4 25
$3.0M
$121.9M
Q3 25
$3.2M
$29.4M
Q2 25
$7.7M
$23.5M
Q1 25
$-13.2M
$42.4M
Q4 24
$8.7M
$141.6M
Q3 24
$3.9M
$40.6M
Q2 24
$4.2M
$19.0M
Free Cash Flow
AXGN
AXGN
WABC
WABC
Q1 26
$-1.4M
Q4 25
$1.8M
$119.7M
Q3 25
$1.7M
$28.7M
Q2 25
$7.0M
$22.8M
Q1 25
$-13.4M
$42.2M
Q4 24
$8.1M
$139.8M
Q3 24
$3.3M
$40.1M
Q2 24
$3.3M
$18.6M
FCF Margin
AXGN
AXGN
WABC
WABC
Q1 26
-2.3%
Q4 25
3.0%
189.0%
Q3 25
2.8%
45.1%
Q2 25
12.4%
35.3%
Q1 25
-27.7%
63.5%
Q4 24
16.3%
201.0%
Q3 24
6.8%
54.1%
Q2 24
6.8%
25.0%
Capex Intensity
AXGN
AXGN
WABC
WABC
Q1 26
Q4 25
2.1%
3.5%
Q3 25
2.5%
1.1%
Q2 25
1.3%
1.1%
Q1 25
0.5%
0.3%
Q4 24
1.4%
2.5%
Q3 24
1.2%
0.7%
Q2 24
1.9%
0.6%
Cash Conversion
AXGN
AXGN
WABC
WABC
Q1 26
Q4 25
4.38×
Q3 25
4.55×
1.04×
Q2 25
13.35×
0.81×
Q1 25
1.37×
Q4 24
19.41×
4.47×
Q3 24
1.16×
Q2 24
0.54×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons